Pneumococcal 20-valent Conjugate Vaccine (Pfizer)

20价肺炎球菌多糖结合疫苗 (辉瑞)

Report date: 2024/12/05 17:18:33

Base Information

Drug NamePneumococcal 20-valent Conjugate Vaccine (Pfizer)
Drug Alias NameMultivalent Pneumococcal conjugate vaccine(Pfizer)RSVpreF（PF-06482077）Pneumococcal conjugate vaccine(Pfizer)PREVNAR 20APEXXNAR +[9] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Development/production technology > Conjugated vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Otitis MediaRespiratory Syncytial Virus Infections +[6] 
Global Approved IndicationsPneumococcal Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/06/08
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Ireland Pharmaceuticals LtdWyeth Pharmaceuticals Fz-LlcWyeth Pharmaceuticals Inc +[8] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Otitis MediaRespiratory Syncytial Virus Infections +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A